Female hair loss: before you buy anything, let's find out which type you have.

Telogen effluvium is always started by a trigger, and the shedding typically appears 2–3 months later, though this window can range from 1 to 6 months: childbirth, severe stress, high fever, surgery, drastic dieting, iron deficiency, thyroid dysfunction. The body sends many hair follicles into the resting phase at once, it's not a lack of stimulation.

Most sudden-onset telogen effluvium resolves on its own once the cause is treated. That's why the first step is a blood test. It's worth asking for two values: ferritin, which shows how much iron is stored in your body, and thyroid function (shown on the lab report as TSH and T4).

Discuss this with your GP or dermatologist, the lab work starts with them. And yes: the two can occur together, the blood test still comes first.

For details, triggers, and workup: telogen effluvium.

On iron stores, ferritin, and what a hair vitamin can do: hair loss and vitamins.

Female pattern hair loss starts down the same path as male pattern baldness. Behind it is a hormone called DHT (full name dihydrotestosterone, which the body produces from testosterone), which shrinks genetically sensitive hair follicles over years. In women, estrogen softens this effect, which is why the process is slower, why the hairline stays put, and why the follicles tend to thin rather than disappear completely.

Important, and often misunderstood: in most cases, blood androgen levels are normal. You don't need a hormonal imbalance to have female pattern hair loss, and a normal lab result doesn't rule it out.

It often first appears around menopause: as estrogen drops, hair follicles become more sensitive.

Microneedling opens temporary microchannels in the skin's outer barrier layer: it triggers a local regenerative response around the follicle. In the studies, minoxidil was added alongside this, not because the stamp "delivers" it. Whether the stamp affects minoxidil absorption at all is something no one has measured.

This mechanism works not through male hormones. That's why it can be relevant even when your androgen levels are normal, and that's exactly the common case in female pattern hair loss.

What we DON'T know: whether a 1 mm at-home stamp affects minoxidil absorption at all. No one has measured it. If you see a percentage for this anywhere, it's a made-up number.

This study compared three groups: minoxidil alone · minoxidil + spironolactone (a prescription drug also used for hair loss in women) · minoxidil + microneedling. The microneedling group produced the largest increase in hair density, and only in this group did the diameter of the hair follicle and the thickness of the epidermis (the skin's outermost layer) increase. ⚠️ The hair shaft itself, however, thickened in all three groups, with no difference between groups here. So this study did not show a "thicker strand" in favor of microneedling.

The honest part: in the study, needling was done every 2 weeks, in a clinic, not weekly at home.

And there's ANOTHER, larger study, also in women, that found no added benefit at all. It was published in 2026 in JAAD, one of the most prestigious dermatology journals (international identifier: PMID 42190753). 245 women took part, all with mild to moderate female pattern hair loss. (The paper describes this as Savin D3–D6: the eight-grade Savin scale classifies crown density, and D3–D6 is its mild-to-moderate range.) In this study, microneedling added on top of minoxidil 2% gave no added benefit over 24 weeks: all three groups improved, but equally.

Two studies, two different results, and this is the REAL difference: the minoxidil dose (5% in the positive one, 2% in the null one) and the device. ⚠️ What can NOT be cited as a difference: the schedule and the setting. The null study also tested the 2-week schedule (with both a monthly and a biweekly arm), and neither showed a benefit, and that too was done in a clinic, at a single center. Nor is it an excuse that it was an "open-label" study (meaning both the participant and the investigator knew which treatment was given). This kind of design usually biases results in favor of the treatment, so if there was still no added benefit even under those conditions, that actually strengthens the null result. We're not sugarcoating this, and that's why the grade is B, not A: there are two directly relevant studies, and they contradict each other.

And the device, honestly in both directions: neither study was done with our 1 mm hand stamp. The positive one used a clinical motorized device, the null one a 36-needle needle cartridge (a swappable needle head that clicks into a motorized device). ⚠️ The null study's needle length was 0.5–0.55 mm (the paper states it in 500–550 micrometers, a thousand micrometers make up a millimeter), which falls within the range we also recommend (0.5–1.0 mm). So this cannot be used to discount the null result. This does not imply that ours is better.

The milestone study's methodology, verbatim: "not to apply Minoxidil on the day of procedure and to resume its application only 24 h after" (Dhurat 2013).

The "you can reapply after half an hour" advice circulating on forums is a community habit. There's no clinical data behind it. 24 hours is the conservative, safe approach.

If you're allergic to minoxidil: never with the Dermastamp, increased penetration would make things worse.